44% of the subjects treated with PERT (6 subjects with T1D, 6 with pancreatogenic diabetes, one with MODY-HNF1B, one with post-PDL1 treatment diabetes and 9 undetermined) and 21% of the control subjects (5 subjects with T1D, 3 with T2D, one with post-transplantation diabetes and 1 undetermined) presented with gastro-intestinal disorders. Here, HNF1B is linked to diabetes mellitus.